drugset / Trial / NCT01715493

Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom

NCT01715493

Phase 4 Completed 48 enrolled Eisai Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

The aim of this study was to assess the effectiveness for small airway inflammation of 4 weeks lysozyme administration in Chronic Obstructive Pulmonary Disease (COPD) and/or asthma.

Timeline

Start
2012-10
Primary completion
2013-12
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lysozyme Unknown 90 mg